Leena Watts
Medicaid is a joint federal and state program that provides health insurance coverage to eligible low-income individuals and families in the US. While some state Medicaid programs cover weight-loss drugs, many do not. The coverage of weight-loss drugs is determined by each state, and as of 2025, 16 states offer weight-loss drug coverage, while 34 states and the District of Columbia do not. The high cost of weight-loss drugs, such as Wegovy and Zepound, is a significant factor in the limited coverage provided by state Medicaid plans. In addition, the demand for these drugs may result in their unavailability, even if covered by Medicaid. While Medicare is prohibited by statute from covering weight-loss drugs, the Biden Administration had planned to allow coverage of these drugs for individuals with obesity on Medicare or Medicaid in 2026. However, the Trump Administration reversed this decision, stating that the proposal was not appropriate at this time.
| Characteristics | Values |
|---|---|
| Medicaid coverage for weight loss drugs | Varies by state; 16 states offer weight-loss drug coverage, 34 states do not |
| Medicaid coverage for weight loss programs | Yes, some state Medicaid programs cover weight loss programs, obesity screenings, bariatric surgery, and gym memberships |
| Medicaid coverage for GLP-1 drugs | Limited, but the number of prescriptions and spending on GLP-1s have increased rapidly in recent years |
| Medicaid coverage for anti-obesity drugs | Will not be covered in 2026 |
| Medicaid coverage for Ozempic | May be covered for eligible individuals, but varies by state |
| Medicaid coverage for Wegovy | May be covered, but depends on the state |
Explore related products
What You'll Learn
GLP-1 drugs for weight loss
Medicaid is a joint federal and state program that provides health insurance coverage to eligible low-income individuals and families in the US. While some benefits are mandatory and must be provided by each state's Medicaid program, others, such as prescription medication coverage, are optional. This means that coverage of weight-loss drugs varies depending on the state running the program.
GLP-1 (glucagon-like peptide-1) drugs are a treatment for type 2 diabetes that has been used for over a decade. However, newer forms of these drugs have gained attention for their effectiveness in treating obesity. GLP-1 drugs work by triggering insulin release, reducing glucose (sugar) production in the liver, and making you feel full. They can be taken as oral pills or subcutaneous injections.
Some GLP-1 drugs that are FDA-approved for weight loss include Wegovy, Saxenda, and Zepbound. Other GLP-1 drugs such as Ozempic are FDA-approved for treating type 2 diabetes, but they can also cause weight loss as a side effect. Medicaid programs must cover formulations to treat type 2 diabetes, so Ozempic may be covered by Medicaid, depending on the state.
As of mid-2025, the most effective GLP-1 drug for weight loss is considered to be tirzepatide, which is marketed under the brand names Mounjaro (for diabetes) and Zepbound (for weight loss). Patients taking tirzepatide lost on average about 8.5 kg (19 lbs), compared to 3 kg (6.6 lbs) for semaglutide, the second-best option.
Healthy Eating for Subclavian Vein Health
You may want to see also
Explore related products
State-by-state variation in coverage
Medicaid is a joint federal and state program that provides health insurance coverage to eligible low-income individuals and families in the US. While some benefits are mandatory and must be provided by each state’s Medicaid program, others, such as prescription medication coverage, are optional.
There is evidence that 26 state Medicaid programs cover nutritional assessment and consultation for obesity. Almost all of these programs offer dietitian referral only if the patient has an obesity-related medical condition. Eleven of the 26 states include various restrictions, and 20 state Medicaid programs explicitly exclude nutritional services for enrollees.
The majority of Medicaid programs will cover bariatric surgery for their enrollees, with restrictions. Between 1998 and 2002, the number of bariatric surgeries covered by Medicaid increased by more than 260%. CMS has expanded coverage of bariatric surgery for Medicare beneficiaries who are morbidly obese, but beneficiaries must have a comorbid condition, such as hypertension, coronary artery disease, osteoarthritis, or type 2 diabetes.
Some states offer coverage for weight-loss medications such as GLP-1 agonists, but only for people who meet certain criteria. Medicaid may cover Ozempic for eligible individuals, but coverage may vary depending on the state. Some state Medicaid plans cover weight-loss medications, but most do not.
Under the Medicaid Drug Rebate Program, Medicaid programs must cover nearly all of a participating manufacturer’s Food and Drug Administration (FDA)-approved drugs for medically accepted indications. However, weight-loss drugs are included in a small group of drugs that can be excluded from coverage. The FDA has approved three GLP-1s for the treatment of obesity: Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide). State Medicaid coverage of these is optional. However, Medicaid programs have to cover formulations to treat type 2 diabetes, including Ozempic (semaglutide), Rybelsus (semaglutide), Victoza (lirglutide), and Mounjaro (tirzepatide).
Carnivore Diet: Ketosis and Its Benefits
You may want to see also
Explore related products
Weight-loss drugs vs. diabetes drugs
Medicaid is a joint federal and state program that provides health insurance coverage to eligible low-income individuals and families in the US. Some benefits are mandatory, while others, such as prescription medication coverage, are optional.
Medicaid and CHIP programs help address the challenge posed by obesity by providing access to screenings and interventions to reduce obesity and promote healthy eating and physical activity. Medicaid and CHIP can cover a range of services to prevent and reduce obesity, including Body Mass Index (BMI) screening, education and counseling on nutrition and physical activity, prescription drugs that promote weight loss, and, as appropriate, bariatric surgery.
GLP-1 (glucagon-like peptide-1) drugs have been used as a treatment for type 2 diabetes for over a decade, but newer forms of these drugs have gained widespread attention for their effectiveness as a treatment for obesity. While these drugs have provided new opportunities for obesity treatment, they are expensive when purchased out of pocket, and coverage in Medicaid, ACA Marketplace plans, and most large employer firms remains limited.
Ozempic (semaglutide) and Wegovy are weight-loss drugs that have gained a lot of attention. Ozempic is approved for people with Type 2 diabetes, while Wegovy is approved for people with obesity or those who are overweight and have health problems related to excess weight. Ozempic is typically covered by health insurance, while Wegovy is often not. Medicaid programs have to cover formulations to treat type 2 diabetes, including Ozempic, but state Medicaid coverage of Wegovy is optional.
It is important to note that if you start taking either of these drugs for weight loss, your body may get used to them, and you may need to keep taking them indefinitely to maintain your weight loss. In addition, these drugs can cause unpleasant gastrointestinal side effects, and a small percentage of people who take them can suffer from a diabetes-related eye complication called retinopathy.
Coconut Oil: Friend or Foe in Mediterranean Diet?
You may want to see also
Explore related products
Obesity-related services
Medicaid is a joint federal and state program that provides health insurance coverage to eligible low-income individuals and families in the U.S. Some benefits are mandatory and must be provided by each state’s Medicaid program, while other benefits, such as prescription medication coverage, are optional.
Medicaid covers a range of obesity-related services, including obesity screenings, bariatric surgery, and other services to help beneficiaries lose weight. Obesity screenings are a mandatory benefit for Medicaid beneficiaries under the age of 21. The Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefit includes obesity screening and is required coverage for all state Medicaid programs. Some states may also provide this benefit for beneficiaries aged 21 and over, though not every state does.
Medicaid covers some weight-loss programs and services, and weight-loss medication as outlined below. Before discussing how Medicaid covers weight loss benefits, it’s important to know how Medicaid coverage is broken down. There is a set of benefits that every state Medicaid program is required to offer. These are called mandatory Medicaid benefits. Once that required coverage is met, states then have some flexibility in terms of other benefits the state Medicare program may cover. These additional benefits are called optional Medicaid benefits.
Medicaid covers prescription drugs that promote weight loss, and, as appropriate, bariatric surgery. Children have access to such services through EPSDT. States can decide what services to cover for adults, and a survey found that a growing number of states cover services like obesity screening and counseling on healthy diets. For example, in 2009, the Michigan Department of Community Health sent a letter to Medicaid providers encouraging them to conduct height, weight, and nutrition assessments as part of all well-child visits.
Medicaid covers some weight-loss medications, but most do not. As of 2024, 16 state Medicaid programs currently offer weight-loss drug coverage, while 34 states, plus the District of Columbia, do not. States that offer some Medicaid coverage for weight-loss medication include Texas and Louisiana, which only offer coverage of a drug called Xenical (orlistat), a lipase inhibitor that prevents the absorption of some dietary fat. Five states—Illinois, Massachusetts, New Mexico, Utah, and Vermont—are also considering adding additional weight-loss medication coverage.
Medicaid may cover Ozempic for eligible individuals, but coverage may vary depending on the state. Ozempic is a medication that’s FDA-approved for Type 2 diabetes and for reducing the likelihood of significant cardiovascular events in adults with Type 2 diabetes and a preexisting heart condition. It can also affect the regions of the brain that control hunger and fullness, which can lead to weight loss. However, the manufacturer's savings card for Ozempic is only valid for diabetes management, not weight loss.
The FDA has approved three GLP-1s for the treatment of obesity: Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide). State Medicaid coverage of these is optional. However, Medicaid programs have to cover formulations to treat type 2 diabetes, including Ozempic (semaglutide), Rybelsus (semaglutide), Victoza (liraglutide), and Mounjaro (tirzepatide). While GLP-1 drugs have provided new opportunities for obesity treatment, they are expensive when purchased out of pocket, and coverage in Medicaid remains limited.
Dysphagia Diet Level 1: What Does It Mean?
You may want to see also
Explore related products
Weight-loss surgery
Medicaid is a joint federal and state program that provides health insurance coverage to eligible low-income individuals and families in the U.S. While traditional Medicaid provides coverage for children, pregnant women, and disabled adults, expanded Medicaid offers insurance to all adults with incomes up to 138% of the federal poverty level.
Medicaid and CHIP programs help address the challenge posed by the increased prevalence of obesity in the U.S. by providing access to screenings and interventions to reduce obesity and promote healthy eating and physical activity. These programs can cover a range of services to prevent and reduce obesity, including Body Mass Index (BMI) screening, education, and counseling on nutrition and physical activity, prescription drugs that promote weight loss, and, as appropriate, bariatric surgery.
Bariatric surgery leads to dramatic weight loss and improved overall health, which may affect insurance status for certain patients. While bariatric surgery has resulted in sustainable weight loss and significant improvements in related comorbidities, such as cardiovascular disease and diabetes mellitus, it has also led to an unintended loss of Medicaid coverage for some patients. In states not expanding Medicaid, successful surgery resulted in over 40% of patients losing Medicaid coverage postoperatively, with half of those patients returning for follow-up with no insurance coverage.
Medicaid coverage for weight-loss medications varies depending on the state. While some states may cover weight-loss medications, others do not. Additionally, states can decide which specific medications will be covered. For example, a state may not cover Wegovy but may cover Saxenda (liraglutide), which is FDA-approved for chronic weight management. Medicaid programs must cover nearly all FDA-approved drugs for medically accepted indications, but weight-loss drugs are included in a small group of drugs that can be excluded from coverage.
Recent studies have shown a rapid increase in the number of Medicaid prescriptions and gross spending on GLP-1 medications, which are effective for weight loss. While coverage for these drugs in Medicaid, ACA Marketplace plans, and most large employer firms remains limited, a growing number of state Medicaid programs are re-evaluating their coverage policies.
Diet and Exercise: Horses and Healthy Habits in January
You may want to see also
Frequently asked questions
Medicaid coverage for diet pills varies from state to state. While some state Medicaid programs cover weight-loss medication, most do not. It is best to check with your state agency to see what your state covers.
Some weight-loss medications covered by Medicaid include Qsymia, Saxenda (liraglutide), Ozempic, and Xenical (orlistat).
Medicaid covers some weight-loss programs, obesity screenings, bariatric surgery, and other services to help beneficiaries lose weight.
![The Law of Health Care Finance and Regulation: [Connected Ebook] (Aspen Casebook)](https://m.media-amazon.com/images/I/7128gr7fHYL._AC_UL320_.jpg)
